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Ya-Ping Hong2, Raymond A Firestone3 and Yan Li1*Abstract
Background: This study was to investigate the effects and safety of cathepsin B-cleavable doxorubicin (DOX)-prodrug
(PDOX) for targeting therapy of metastatic human hepatocellular carcinoma (HCC) using DOX as a positive control drug.
Methods: The orthotopic nude mice model of highly metastatic HCC was established and the animals were
randomized and treated with PDOX, DOX and saline, respectively. Hematology, biochemistry and tumor markers were
studied. At autopsy, liver tumor weight and size, ascites, abdominal lymph nodes metastases, experimental peritoneal
carcinomatosis index (ePCI), and tumor-host body weight ratio were investigated. Immunohistochemical studies and
western blotting were done to investigate key molecules involved in the mechanism of action.
Results: Compared with Control, both PDOX and DOX could similarly and significantly reduce liver tumor weight and
tumor volume by over 40%, ePCI values, retroperitoneal lymph node metastases and lung metastases and serum AFP
levels (P < 0.05). The PDOX group had significantly higher WBC than the DOX group (P < 0.05), and higher PLT than
Control (P < 0.05). Serum BUN and Cr levels were lower in the PDOX group than DOX and Control groups (P < 0.05).
Compared with Control, DOX increased CK and CK-MB; while PDOX decreased CK compared with DOX (P < 0.05).
Multiple spotty degenerative changes of the myocardium were observed in DOX-treated mice, but not in the Control
and PDOX groups. PDOX could significantly reduce the Ki-67 positive rate of tumor cells, compared with DOX and
Control groups. PDOX produced the effects at least via the ERK pathway.
Conclusion: Compared with DOX, PDOX may have better anti-metastatic efficacy and reduced side effects especially
cardio-toxicities in this HCC model.
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Hepatocellular carcinoma (HCC) is the fifth most frequent
malignant tumors, and the third leading cause of
cancer-related mortality in the world [1]. HCC patients
are usually diagnosed when the tumor is in an advanced
stage and lose the opportunity for curative surgery [2].
Other treatments including loco-regional or systemic* Correspondence: liyansd2@163.com
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reproduction in any medium, provided the orchemotherapy, fail mainly due to the chemoresistance of
tumor and inability to endure treatment responses [3].
One of the most commonly used chemotherapy drugs
for HCC is doxorubicin (DOX), but high doses of DOX
result in severe toxicities, such as hematological, gastro-
intestinal, renal, hepatic toxicities, and particularly cardiac
toxicities [4-6].
Increasing evidence supports the role of cathepsin B
(Cat B) in tumor invasion and metastasis [7-9], including
HCC progression [10]. Cat B expression is increased in
many cancers at the mRNA, protein and activity levels,
and closely related to invasive behavior of cancer [11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drugs designed specifically against invading cancer cells.
To retain the therapeutic effect while reducing the tox-
icity of DOX, Dubowchik et al. [12-14] designed a smart
prodrug of DOX, Ac-Phe-Lys-PABC-DOX (PDOX), in
which a Cat B-specific dipeptide is introduced, along
with a spacer PABC (para-aminobenzyloxycarbonyl) to
increase the distance between dipeptide and DOX, so
that the dipeptide can enter the Cat B’ active site. As a
result of this molecular re-structuring, the prodrug is
inactive in blood circulation and normal tissues where
little Cat B exists in the active form. When the prodrug
reaches Cat B-enriched area such as the invasion front of
cancer, the Phe-Lys dipeptide is cleaved by Cat B, exposing
the PABC spacer that is then hydrolyzed spontaneously,
releasing free DOX at the cancer invasion front. Thus
this prodrug could exert cytotoxicity to invading cancer
cells while protecting normal cells from excessive drug
exposure, a strategy called passive targeted therapy.
In our previous animal model study, we investigated
the activities and side effects of PDOX to treat peritoneal
carcinomatosis (PC) from gastric cancer, which suggests
that PDOX might be a promising new drug against cancer
invasion [15]. Inspired by the initial results, we designed
this study to further explore the treatment potential of
this prodrug in a more aggressive and highly lethal
orthotopic nude mice model of HCC.
Materials and methods
Agents and drugs
The prodrug PDOX was synthesized according to the
previously reported chemical process [12-14]. The mo-
lecular formula of PDOX is C52H59N5O16 · HCl, and the
molecular weight is 1046.51. In terms of equivalent mole
content, 1.8 mg PDOX is equivalent to 1 mg DOX (mo-
lecular weight 579.99). Doxorubicin for injection (DOX,
Pharmacia, Milan, Italy, 10 mg per vial) was obtained
commercially.
HCC cell lines and animal models
Highly metastatic human HCC cell line HCCLM9 was
used for animal model construction. This cell line was
obtained by cloning culture, and 9 rounds of successive
in vivo pulmonary metastases selections as described
previously [16,17]. Cells were grown in RPMI 1640
medium (Mediatech, Manassas, VA) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin/strepto-
mycin (Gibco, Carlsbad, CA). The cells were cultured in
a humidified atmosphere at 37°C in 5% CO2 and passaged
if grown to 90% confluence.
Orthotopic nude mice model of HCC and treatment
Male athymic BALB/c nu/nu mice, 4–6 weeks old, were
obtained from Beijing HFK Bio-Technology Co. Ltd[animal quality certificate No. SCXK (jing) 290004] and
housed in specific pathogen-free (SPF) condition at the
Animal Experiment Center of Wuhan University. All
animal experiments were carried out in accordance with
the guidelines and approved protocols of the University
of Wuhan Animal Experiment Center Institutional Animal
Care and Use Committee (Permit Number 00024763).
Nude mice model with spontaneous pulmonary metas-
tasis was established as described previously [17]. Briefly,
HCCLM9 cells (5 × 106 cells each) in 0.1 ml phosphate
buffered saline (PBS) were injected subcutaneously into
the left upper flank of 2 nude mice. The subcutaneous
tumors were removed when they reached 8 mm in
diameter, and minced into pieces (1 mm3) to perform
orthotopic transplantation into livers of nude mice (n =
33). On day 8 after model establishment, the mice were
randomized into Control group (n = 10), DOX group
(n = 11), and PDOX group (n = 12), and treated as illus-
trated in the flow chart of Figure 1 (Figure 1A).
In our previous study [15], we found that by intraperi-
toneal injection, PDOX could be safely administered at
twice the dose of DOX on a molar basis. Therefore, we
increased the doses of both DOX (4 mg/kg) and PDOX
(21.6 mg/kg) in this study, in which the PDOX dose was
3 times that of DOX on a molar basis.
The behaviors and general conditions were monitored
daily, and body weights of animals were recorded twice
a week. On d 36 post inoculation, the mice were anes-
thetized by peritoneal injection of 3% phenobarbital
chloride, and then subjected to magnetic resonance
image (MRI) study to measure the liver tumor size
(Bruker Biospec 4.7 T/30, Germany). The peripheral
blood was obtained for routine blood tests and biochemis-
try studies. Tumor tissues and major organs including
the heart, the liver, the lungs and any other suspected
organs were collected, fixed with 4% paraformaldehyde
and embedded in paraffin for pathological and immuno-
histochemistry studies. In addition, fresh tumor tissues were
obtained for western blotting studies as detailed below.
Experimental peritoneal carcinomatosis index (ePCI)
An experimental peritoneal carcinomatosis index (ePCI)
system was developed to evaluate the efficacy that took
into consideration of tumor nodule sizes, distributions,
and the characteristics of ascites. In this system, the
abdominal cavity of the mouse was divided into 4 regions:
region I, subdiaphragm; region II, the liver, spleen, stom-
ach, and affiliated ligaments; region III, the small intestine,
colon, mesenterium, and abdominal wall; and region
IV, the pelvic cavity, urogenital system, and rectum.
The detailed scoring criteria were modified from a
similar reporting system on a rat peritoneal carcin-
omatosis model [18] and set forth in our previous re-
port [15].
Figure 1 (See legend on next page.)
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Figure 1 The study procedure and major results. A: The flow chart of this study. Nude mice were kept for 3 d of adaptation, and orthotopic
model of human HCC was constructed as described in the Materials and Methods section. On d 8, the animals were randomized into 3 groups,
and treated by tail vein injection of normal saline, DOX and PDOX, respectively. At the study endpoint, all animals were euthanized, and detailed
pathological studies. B: The general status of animals appeared best in the PDOX, better in DOX, and worst in Control that were only 8 animals
because 2 nude mice died before the study endpoint due to excessive tumor burden. C: The body weight curves at different time points show
similar changes in the PDOX and DOX. In Control, there was a progressive increase on the last 6 d, due to accelerated tumor growth and
increased ascites. D-I: Representative MRI scans of the liver tumors in Control (D for T1 and E for T2), the DOX (F for T1 and G for T2) and the
PDOX (H for T1 and I for T2) showed marked differences in tumor size. J: Both PDOX and DOX had similar and significant liver tumor growth
inhibition compared with Control that 2 animals died on the morning of d 36, therefore only 8 tumors were available in the final picture
presentation. K & L: PDOX and DOX treatments significantly reduced retroperitoneal lymph nodes metastases (arrows) compared with Control.
M & N: The lung metastases (arrows) were also significantly reduced in the PDOX and DOX, and PDOX had greater inhibitory effect on lung
metastases than. DOX. D: day; T1: T1-weighted image; T2: T2-weighted image; K & M: hematoxylin and eosin stain, 200×, scale bar = 50 μm.
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Tumor tissues obtained from animals of 3 groups were
subjected to immunohistochemistry to detect the ex-
pressions of Cat B, Ki-67, CD34, VEGF, E-cadherin and
D2-40, according to our previously reported procedures
[15]. The primary antibodies for Cat B (Cat No 3190–
100, BioVision, CA, USA, dilution 1:200), Ki-67 (MAB-
0129, Maxim-Bio Co, CHN, Working solution), CD34
(BA0532, WuHan Boster Bio-Engineering Co, CHN, di-
lution 1:100), VEGF (RB-9031, Maxim-Bio Co, CHN,
Working solution), E-cadherin (MAB-0589, Maxim-Bio
Co, CHN, Working solution) and D2-40 (AM0103, Ascend
Biotechnology Co, CHN, Working solution) were prepared
and incubated with the slides for 2 h in a moist chamber.
After a new cycle of washes, the slides were again
placed in a moist chamber for 30-minute incubation
with a biotinylated secondary antibody and biotin-
peroxidase complex (Biogenex, SF, USA, Working so-
lution). The color of immunoperoxidase reaction was
achieved by immersion for 5 min in a solution con-
taining the DAB chromogen (3,5-diamino-benzidine
tetra-hydrochloride) and counterstained with hema-
toxylin for 2 min. The slides were observed under the
microscope.
For the evaluation of IHC results, positive cells were
stained brownish granules in the cell membrane, cyto-
plasm or nucleus. In all cases, cytoplasmic Cat B
expression was scaled as moderate and strong expres-
sion. Ki-67 expressed in the nucleus. VEGF positive
cells were stained both in the nucleus and cytoplasm.
The expression of E-cadherin mainly existed in cell
membrane and cytoplasm. CD34 and D2-40 positive
cells were stained in cytoplasm. Ten fields in each
slide were selected randomly and observed at a magni-
fication of × 200. The expression of Ki-67 was evalu-
ated according to positive rate. The positive expression
of CD34 and D2-40 was evaluated according to
microvessel density (MVD) and lymphatic microvessel
density (LMVD).Western blotting study
Fresh tumor tissues in RIPA lysis buffer containing 1 μg/
ml PMSF, 1 × Cocktail, were manually homogenized on
ice using a glass homogenizer, then centrifuged at 3000 g
for 10 min to remove cellular and nuclear debris. The
protein concentration was determined using a BCA
Assay kit (Biyuntian).
To determine the expressions of p-ERK1/2, ERK1/2,
Bcl-2, caspase-3, and β-actin using western blotting,
100 μg total proteins were separated by SDS-poly-
acrylamide gel electrophoresis (4% stacking and 10%
separating gels) and then transferred overnight onto
PVDF membranes, which were blocked with 5% skimmed
milk in 0.01 M phosphate buffer solution (PBS) containing
0.05% (v/v) Tween. Next, they were immunoblotted with a
rabbit anti-human p-ERK (4370, CST, MA, USA, dilution
1:1000), rabbit anti- human ERK (4695, CST, MA, USA,
dilution 1:1000), rabbit anti-human Bcl-2 (2870, CST,
MA, USA, dilution 1:1000), rabbit anti-human caspase-3
(9665, CST, MA, USA, dilution 1:1000), mouse anti-
human caspase-9 (9508, CST, MA, USA, dilution
1:1000), and rabbit anti-human β-actin (Santa Cruz,
CA, USA, dilution 1:1000) for 3 h. Blots were then in-
cubated with a peroxidase-conjugated sheep anti-rabbit
IgG (Santa Cruz, CA, USA, dilution 1:8000) or sheep
anti-mouse IgG (Santa Cruz, CA, USA, dilution 1:8000)
for 2 h and developed using chemiluminescent detection
with a Supersignal West Pico assay kit (Thermo, IL, USA)
and autoradiography film.
Blood tests and biochemistries
On d 36, animals were euthanized, and blood was ob-
tained for routine studies, including peripheral blood
profiles by Sysmex KX-21 automated hematology analyzer
(Sysmex, Kobe, Japan); liver function parameters alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
gamma-glutamyl transpeptidase (GGT), total bilirubin
levels (TBIL), and direct bilirubin (DBIL) levels; renal
function parameters blood urea nitrogen (BUN) and
Table 1 Effects on tumor growth and metastases
Items Treatment groups P value
Control (n = 10) DOX (n = 11) PDOX (n = 12)
Value Inhibition ratio☆ Value Inhibition ratio☆
Liver tumor growth
Tumor weight (mg) 6657.4 ± 1312.9*,§ 3860.0 ± 1023.6 42.0% 3757.6 ± 603.5 43.6% * <0.001 vs DOX
§ <0.001 vs PDOX
Tumor volume (mm3) 4965.2 ± 2112.4*,§ 2526.9 ± 1360.1 49.1% 2313.2 ± 675.7 53.4% * <0.05 vs DOX
§ <0.001 vs PDOX
TW/BW ratio 27.94 ± 4.10*,§ 18.28 ± 4.12 34.5% 18.10 ± 3.18 35.2% * <0.001 vs DOX
§ <0.001 vs PDOX
AFP level (ng/mL) 97.27 ± 34.22*,§ 24.69 ± 12.09 74.6% 22.31 ± 13.42 77.1% * <0.001 vs DOX
§ <0.001 vs PDOX
ePCI 9 ± 2*,§ 6 ± 2 33.3% 6 ± 2 33.3% * <0.05 vs DOX
§ <0.05 vs PDOX
Tumor metastases
Mediastinal LN meta 70.0% (7/10) 63.6% (7/11) 9.1% 33.3% (4/12) 52.4% >0.05
Lung meta 100% (10/10) *,§ 63.6% (7/11)# 36.4% 33.3% (4/12) 66.7% * <0.05 vs DOX
§ <0.05 vs PDOX
# <0.05 vs PDOX
Diaphragm meta 90% (9/10) 72.7% (8/11) 19.2% 50% (6/12) 44.4% >0.05
Intrahepatic meta 30% (3/10) 27.3% (3/11) 9.0% 50% (6/12) −66.7% >0.05
Spleen ligament meta 70% (7/10) 36.4% (4/11) 48.0% 41.7% (5/12) 40.4% >0.05
Heptogastric ligament meta 90% (9/10) 90.9% (10/11) −1.0% 83.3% (10/12) 7.4% >0.05
Renal ligament meta 40.0% (4/10) 36.4% (4/11) 9.0% 58.3% (7/12) −45.8% >0.05
Adrenal meta 10.0% (1/10) 0.0% (0/11) 100% 0.0% (0/12) 100% >0.05
Mesenteric meta 90.0% (9/10) 81.8% (9/11) 9.1% 58.3% (7/12) 35.2% >0.05
Retroperitoneal LN meta 80.0% (8/10) *,§ 27.3% (3/11) 65.9% 16.7% (2/12) 79.1% * <0.05 vs DOX
§ <0.05 vs PDOX
Abdominal wall meta 80.0% (8/10) 45.5% (5/11) 43.1% 66.7% (8/12) 16.6% >0.05
Bloody ascites 50.0% (5/10) 9.1% (1/11) 81.8% 25.0% (3/12) 50.0% >0.05
TW: tumor weight; BW: body weight; AFP: alpha-fetoprotein; ePCI: experimental peritoneal carcinomatosis index; LN: lymph nodes; Meta: metastasis.
☆All the inhibition ratios were compared with the Control group. *,§, #: denote statistical significances for comparisons of the same item in different groups, as
clearly described in the P value column.
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kinase (CK), creatine kinase-MB (CK-MB) and lactate
dehydrogenase (LDH) levels; electrolytes (K+, Na+, Ca2+,
Mg2+ and Cl-) and serum alpha fetoprotein (AFP) levels;
all by Aeroset Clinical Chemistry Analyzer (Abbott La-
boratories, IL, USA).Statistical analysis
All data were analyzed using the statistical software of
SPSS 13.0 for Windows (SPSS Inc, Chicago, USA). The
differences in body weights, liver tumor weights, and the
expression of Ki-67, CD34 and D2-40 among different
groups were tested by one-way ANOVA. The differences
of Cat B, VEGF and E-cadherin were analyzed by the
chi-square (χ2) test. P-value < 0.05 was considered as sta-
tistically significant.Results
PDOX had better effects on general status and similar
inhibitory effects on liver tumor growth and
loco-regional metastases
After tumor inoculation into the liver, the animals in the
DOX and PDOX groups showed slight and progressive
body weight decreases till the study endpoint. The gen-
eral status of animals appeared better in the PDOX
group than the DOX group, which in turn was better
than Control group (Figure 1B). In the Control group,
the animals showed body weight increases from d 30 to
d 36, mainly due to excessive liver tumor and ascites
(Figure 1C).
Prominent liver tumors were observed in all animals,
and representative MRI abdominal scan of liver tumors
were shown (Figure 1D to 1I). At the study endpoint,
the tumor weights were 6657.4 ± 1312.9 mg in the
Table 2 Immunohistochemical analysis
Items Treatment groups P value
Control (n = 10) DOX (n = 11) PDOX (n = 12)
Cat B 100% (10/10) 10% (11/11) 100% (12/12) P > 0.05
VEGF 100% (10/10) 90.9% (10/11) 83.3% (10/12) P > 0.05
E-cadherin 100% (10/10) 90.9% (10/11) 100% (12/12) P > 0.05
Ki-67 77.1 ± 7.8%* 72.3 ± 4.9%# 61.6 ± 14.6% *P < 0.05, Control vs PDOX #P < 0.05, DOX vs PDOX
CD34 47.2 (21.4-70.0) 60.9 (37.0-91.2) 55.6 (22.2-80.2) P > 0.05
D2-40 0.5 (0.0-3.2) 1.8 (0.0-8.4) 1.8 (0.0-5.8) P > 0.05
Notes: Cat B, VEGF and E-cadherin were evaluated according to the percentage of positive expression (number of animals with positive expression ÷ number of
all animals in the group × 100%). The expression of Ki-67 was evaluated according to positive rate in every animal. The positive expression of CD34 and D2-40 was
evaluated according to microvessel density (MVD) and lymphatic microvessel density (LMVD).
*, #: denote statistical significances for comparisons of the same item in different groups, as clearly described in the P value column.
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and 3757.6 ± 603.5 mg in the PDOX group (P < 0.001,
Control vs PDOX; P < 0.001, Control vs DOX; P > 0.05,
DOX vs PDOX). Compared with Control, PDOX and
DOX treatments reduced tumor weights by 43.6% and
42.0%, respectively. Similarly, PDOX and DOX treat-
ments reduced tumor volumes by 53.4% and 49.1%, re-
spectively (P < 0.01, DOX/PDOX vs Control) (Figure 1J,
Table 1). The tumor-weight to body-weight ratio was
also significantly reduced from 27.94% in the Control
group to 18.28% in the DOX group and 18.10% in
the PDOX group (P < 0.001, DOX/PDOX vs Control).
The serum AFP level was reduced from 97.27 ±
34.22 ng/mL in the Control group to 24.69 ± 12.09
ng/mL in the DOX group and 22.31 ± 13.42 ng/mL in
the PDOX group (P < 0.001, DOX/PDOX vs Control)
(Table 1).
In addition to liver tumor reduction, the loco-regional
metastases were also investigated. We used the ePCI
score system to evaluate the peritoneal metastases of this
model. The ePCI was reduced from 9 ± 2 in the Control
group to 6 ± 2 in the DOX group and 6 ± 2 in the PDOX
group (P < 0.05, DOX/PDOX vs Control). Another sig-
nificant effect was observed on retroperitoneal lymph
node metastases, which occurred in 80.0% (8/10), 27.3%
(3/11) and 16.7% (2/12) of animals, respectively, in the
Control, DOX and PDOX groups (P < 0.05, DOX/PDOX
vs Control) (Figure 1K and 1L, Table 1).PDOX had better inhibitory effects on lung metastases
than DOX
Treatment effects on distant metastases were also stud-
ied. The rates of animals with lung metastases were re-
duced from 100.0% (10/10) in the Control group to
63.6% (7/11) in the DOX group and 33.3% (4/12) in the
PDOX group (P < 0.05, Control vs DOX; P < 0.05, Con-
trol vs PDOX; P < 0.05, DOX vs PDOX) (Figure 1M and
1N, Table 1).PDOX had higher inhibitory effect on tumor proliferation
than DOX
IHC studies were performed to investigate the expression
of major cancer molecules possibly affected by the treat-
ments. As shown in Table 2 and Figure 2, positive cyto-
plasmic Cat B expression was observed in all tumors
from the 3 groups. Ki-67 positive rates were 77.1 ± 7.8%
in the Control group, 72.3 ± 4.9% in the DOX group,
and 61.6 ± 14.6% in the PDOX group (P > 0.05, Control
vs DOX; P < 0.05, Control vs PDOX; P < 0.05, DOX vs
PDOX). The median (range) MVD values of CD34 were
47.2 (21.4-70.0) in the Control group, 60.9 (37.0-91.2)
in the DOX group, and 55.6 (22.2-80.2) in the PDOX
group, respectively (P > 0.05). The VEGF positive rate
was not statistically different among the 3 groups (P >
0.05). Similarly, there was no statistical difference in
the expression of E-cadherin among the 3 groups (P >
0.05). The median (range) values of LMVD designated
as D2-40 positive expression were 0.5 (0.0-3.2), 1.8
(0.0-8.4) and 1.8 (0.0-5.8) in the Control, DOX and
PDOX groups, respectively (P > 0.05).PDOX had less hematological and biochemical toxicities
than DOX
The hematological and non-hematological toxicities were
studied (Table 3). In peripheral blood routine, the white
blood cells levels in PDOX mice were higher than DOX
mice (1.98-folds, P < 0.05). The platelet levels were higher
in the PDOX group (1.67-folds, P < 0.05) and the DOX
group (1.59-folds, P > 0.05) compared with Control. There
were no differences in red blood cells and hemoglobin
levels among the 3 groups.
In terms of liver functions, compared with Control,
DOX and PDOX caused significant reduction in GGT
and AST levels (P < 0.05, DOX/PDOX vs Control)
(Table 3). There were no statistically significant differ-
ences in AST, TBIL and DBIL levels among the 3
groups.
Figure 2 Immunohistochemical studies on key molecules in tumor growth and metastases. C1, D1 & P1: the cytoplasmic expression of
Cat B in 33 tumors was similar among the 3 groups. C2, D2 & P2: The Ki-67 positive rate in the Control group (C2, 77.1%) was significantly higher
than those in the DOX group (D2, 72.3%) and the PDOX group (P2, 61.6%) (Control vs DOX: P < 0.05, Control vs PDOX: P < 0.05, DOX vs PDOX:
P < 0.05). C3, D3 & P3: The CD34 positive micro-vessels density was similar among the 3 groups. C4, D4 & P4: The rates of VEGF positive cells
were similar among 3 groups. C5, D5 & P5: The positive expression of E-Cadherin was similar among the 3 groups. C6, D6 & P6: The D2-40
positive lymph vessels were also similar among the 3 groups. C: Control; D: DOX; P: PDOX. 400×, scale bar = 20 μm.
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both DOX and PDOX resulted in significant reduction
in serum BUN levels (P < 0.001, Control vs DOX; P <
0.05, Control vs PDOX), and BUN levels in the PDOX
group were also significantly lower than those in the
DOX group (P < 0.05). Furthermore, the serum Cr levels
in the PDOX group were much lower than those of the
Control and DOX groups (P < 0.05, PDOX vs Control;
P < 0.05, PDOX vs DOX) (Table 3).Electrolytes results demonstrated that Cl- was reduced
in PDOX compared with Control group (P < 0.05); But
Ca2+ was increased in PDOX compared with the Control
and DOX groups (P < 0.05, PDOX vs Control; P < 0.05,
PDOX vs DOX) (Table 3).
PDOX had less cardio-toxicity than DOX
Cardiac functions demonstrated that both DOX and PDOX
significantly decreased LDH compared with Control group
Table 3 Routine blood tests and biochemistry (expressed as mean ± SD)
Items Treatment groups P value
Control (n = 8)☆ DOX (n = 11) PDOX (n = 12)
Peripheral blood routine
RBC (×1012/L) 8.06 ± 3.50 9.59 ± 0.65 9.52 ± 1.47 > 0.05
HGB (g/L) 139.00 ± 9.82 141.18 ± 9.62 138.83 ±19.52 > 0.05
WBC (×109/L) 3.25 ± 1.50 2.71 ± 1.00* 5.37 ± 3.31* < 0.05
PLT (×109/L) 385.67 ± 102.72*, § 611.36 ± 176.40 644.33 ± 293.34 * < 0.05 vs DOX
§ < 0.05 vs PDOX
Liver functions
AST (U/L) 489.01 ± 95.85* 338.42 ± 75.47§ 444.64 ± 114.01 * < 0.05 vs DOX
§ < 0.05 vs PDOX
ALT (U/L) 172.83 ± 52.26 219.56 ± 165.57 216.11 ± 153.50 > 0.05
TBIL (μmol/L) 3.51 ± 0.42 3.40 ± 0.50 3.59 ± 0.67 > 0.05
DBIL (μmol/L) 3.21 ± 0.10 3.17 ± 0.11 3.19 ± 0.16 > 0.05
GGT (U/L) 30.28 ± 10.65 *, § 15.75 ± 6.13 18.43 ± 11.06 * < 0.05 vs DOX
§ < 0.05 vs PDOX
Renal functions
BUN (mmol/L) 15.83 ± 1.72*, § 11.99 ± 3.33 # 9.29 ± 2.40 * < 0.05 vs DOX
§ < 0.001 vs PDOX
# < 0.05 vs PDOX
Cr (μmol/L) 41.73 ± 3.85* 43.37 ± 4.95§ 34.76 ± 7.67 * < 0.05 vs PDOX
§ < 0.05 vs PDOX
Electrolytes
K+ (mmol/L) 6.56 ± 0.60 6.58 ± 0.36 6.81 ± 0.59 > 0.05
Na+ (mmol/L) 160.82 ± 4.04 158.53 ± 2.21 158.50 ± 2.54 > 0.05
Cl- (mmol/L) 114.88 ± 1.86* 113.23 ± 2.66 112.42 ± 1.58* < 0.05
Ca2+ (mmol/L) 2.25 ± 0.10* 2.31 ± 0.08§ 2.38 ± 0.08 * < 0.05 vs PDOX
§ < 0.05 vs PDOX
Mg2+ (mmol/L) 1.15 ± 0.09 1.23 ± 0.18 1.15 ± 0.34 > 0.05
☆ Note: Two nude mice died before the study endpoint, leaving only 8 mice available for blood test of routine and biochemistry parameters. *,§, #: denote
statistical significances for comparisons of the same item in different groups, as clearly described in the P value column.
WBC: white blood cell; NEUT: neutrophil; RBC: red blood cell; HGB: hemoglobin; PLT: platelet; LYM: lymphocyte; PLT: platelet count; ALT: alanine transaminase; AST:
aspartate aminotransferase; TBIL: total bilirubin; DBIL: direct bilirubin; GGT: γ-glutamyltransferase; Cr: creatinine; BUN: Blood urea nitrogen; CK: creatine kinase;
CK-MB: creatine kinase-myoglobin; LDH: lactic dehydrogenase.
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differences between the DOX and PDOX groups. Com-
pared with Control, DOX increased CK and CK-MB
levels, although the differences didn’t reach the statistical
significance. On the other hand, PDOX significantly de-
creased CK, compared with DOX (P < 0.05) (Figure 3A,
3B and 3C).
Histopathological study revealed multiple spotty de-
generative changes in the myocardium in DOX-treated
mice (Figure 3F and 3G). There were no observable
histopathological changes in both Control and PDOX
groups (Figure 3D, 3E, 3H and 3I).
PDOX produced the effect at least by the ERK pathway
To investigate the mechanism of PDOX producing ef-
fects, we used western blotting to study the expression
of ERK, p-ERK, BCL-2, caspase-3, and caspase-9. Theresults showed that PDOX and DOX reduced ERK phos-
phorylation, decreased BCL-2 expression, and activated
caspase-3 and caspase-9 (Figure 4).
Discussion
Major treatment modalities for HCC are surgery, che-
motherapy, regional therapies such as radiofrequency
ablation, transarterial chemoembolization (TACE) and
molecular targeting therapies. In either systemic chemo-
therapy or TACE, DOX is one of the most commonly used
drugs with proven efficacy, but has serious side effects.
Among 475 patients who received DOX in various studies,
a 16% response rate was documented, with a median sur-
vival time of 3–4 months [19]. Significant grade 3 or above
hematologic and gastrointestinal toxicities were encoun-
tered in patients treated with DOX, including neutropenia
(63%), febrile neutropenia (17%), thrombocytopenia (24%),
Figure 3 The cardio-toxicities of animals in the 3 groups. A: Compared with Control, DOX increased CK levels but without statistical
significance, while PDOX significantly decreased CK levels compared with DOX (P < 0.05). B: Compared with Control, DOX increased CK-MB levels
without significant difference, but PDOX did not increase CK-MB levels. C: Both DOX and PDOX significantly decreased LDH compared with
Control group (P < 0.05 and P < 0.05). D & E: There were no observable histopathological changes in the myocardium of the Control mice. F & G:
Multiple spotty degenerative changes were observed in the myocardium of the DOX-treated mice. H & I: There were no observable
histopathological changes in the myocardium of the PDOX-treated mice.
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Therefore, it is imperative to modify DOX molecules in
order to reduce its toxicities while maintaining its efficacy.
To fulfill this unmet clinical demand, Dubowchik et al.
[12-14] designed a smart prodrug of DOX, which targets
the active invading cancer cells and spares normal cells,
because cancer cells, but not normal ones, secrete extra-
cellular Cat B. It had previously been determined [12]
that PDOX is stable in human and mouse blood. Themajor question, then, was whether PDOX reaches the
tumor, is cleaved rapidly by Cat B, and the free DOX
then enters into the cancer cells before it diffuses away.
We now report, in this and in our previous paper [15],
that PDOX indeed displays antitumor power at least
equal to that of free DOX.
In this experimental study on a highly metastatic ani-
mal model of HCC, PDOX showed tumor inhibition
similar to that of DOX, but significantly reduced toxicity
Figure 4 Western blotting showed that compared with Control,
PDOX and DOX reduced ERK phosphorylation, decreased BCL-2
expression, and increased caspase-3 and caspase-9 activation.
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ily as free DOX, but is efficiently cleaved to free DOX
there. In terms of liver tumor reduction, both PDOX
and DOX treatments resulted over 40% of tumor growth
inhibition. The general status of animals at the study
endpoint also appeared better in the PDOX group.
These results suggest that PDOX is at least as effective
as DOX in this animal model.
Another possibility is that metastatic cells, which dis-
play more Cat B than those in the primary tumor [11],
might have increased sensitivity to PDOX, and indeed
they do. The primary tumor inhibition ratios relative to
control by PDOX and DOX were 43.6% and 42.0%. In
contrast, the metastases inhibition ratios relative to
control by PDOX and DOX were 52.4% and 9.1% for
mediastinal lymph nodes metastasis, 66.7% and 36.4%
for lung metastasis, 44.4% and 19.2% for diaphragm
metastasis, 35.2% and 9.1% for mesenteric metastasis,
and 79.1% and 65.9% for retroperitoneal lymph nodes
metastasis (Figure 1K and 1L, Table 1). As these are the
principal sites of metastases of HCC, the superiority of
PDOX over free DOX toward metastasis is remarkable
and to our knowledge unprecedented, for usually me-
tastases are more resistant than primaries to chemo-
therapy. It seems likely that the 3:1 molar excess of
PDOX over DOX is more visible with metastasis than
with the primary tumor because metastatic cells secrete
more Cat B per cell than the primary.In terms of toxicities, PDOX has shown advantages
over DOX, even though the dosage of PDOX was 3
times that of DOX in this study. The peripheral blood
cells counts such as WBC and PLT levels were signifi-
cantly higher in the PDOX group than the DOX group,
suggesting less bone marrow toxicity of PDOX. Moreover,
serum BUN and Cr levels were also significantly lower
in the PDOX group than the DOX group, suggesting
less renal toxicity of PDOX. The most remarkable ob-
servation was the reduced cardio-toxicity in the PDOX
group, compared with DOX, as demonstrated by CK,
CK-MB, and LDH levels, and histopathological changes.
Taking together, these facts support the notion that PDOX
has increased anti-metastasis efficacy but reduced toxic-
ities compared with DOX.
In order to explore the potential mechanisms of action
of PDOX, we performed an IHC study and western blot-
ting. Among the parameters investigated by IHC, we
found that Cat B expression was strong in all tumors,
providing supporting evidence that PDOX could pro-
duce the effect by this enzyme. Among other parameters
related to tumor proliferation and invasion, Ki-67 reduction
is the most prominent one in PDOX treated tumors.
PDOX could reduce the Ki-67 positive rate by at least 15%
compared with Control, and by at least 11% compared with
DOX. The Ki-67 is expressed in all the other phases of the
cell cycle except G0 phase, making it a reliable marker of
active cell proliferation. High expression of Ki-67 has been
linked with poor prognosis in prostate, breast, lung and
hepatocellular carcinoma [21-24]. Therefore, significant
reduction in Ki-67 positive rate could at least account
for the fact that PDOX had better tumor inhibition
than DOX in this study, although the difference be-
tween them did not reach statistical significance.
In addition to tumor proliferation parameters, tumor
angiogenesis and lymphoangiogenesis were also studied.
The expression of CD34 and VEGF positive endothelial
cells may play an important role in understanding the
process of angiogenesis in HCC and metastasis [25-27].
D2-40 and E-cadherin may provide important insights
into the process of tumor-associated lymphangiogenesis
[28-30]. In this study, the expressions of VEGF, CD34, D2-
40 and E-cadherin were positive in all tumors, but there
were no statistical differences among 3 groups. Therefore,
we speculate that PDOX did not have different effects on
tumor angiogenesis, lymphangiogenesis and cell adhesion.
The extracellular signal-regulated kinase (ERK) signal-
ing pathway plays an important role in tumor invasion
and metastasis [31,32]. Our study demonstrated that
DOX and PDOX reduced ERK phosphorylation and
BCL-2, activated casepase-3 and caspase-9, suggesting
that PDOX produced the effect at least via ERK pathway.
Presently, knowledge regarding the biological processes
of hepatocarcinogenesis has expanded significantly
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volved in HCC development. Among these molecules,
growth factors and neoangiogenesis factors with their re-
ceptors, tyrosine kinase intracellular enzymatic path-
ways and intracellular signal transmission factors have
been under intensive study [33]. These substances repre-
sent potential molecular targets for targeted therapies
with highly specific small molecules such as sorafenib,
sunitinib, brivanib, cetuximab, erlotinib and lapatinib,
which have emerged as promising therapeutic approaches
for advanced HCC [34,35]. Many other molecular targeting
agents to block epidermal growth factor receptor (EGFR),
vascular endothelial growth factor receptor (VEGF),
platelet-derived growth factor receptor (PDGFR), and
mammalian target of rapamycin (mTOR) are also at
different stages of clinical development for the treat-
ment of advanced HCC [36-38].
The most successful drug of this kind is sorafenib, an
orally-active multikinase inhibitor targeting both tumor
cells and the tumor vasculature. It is the first agent to
improve the overall survival of patients with advanced
HCC, has been approved for molecular targeted therapy
for patients with advanced HCC [39], representing a
landmark success in the treatment of advanced HCC
[40], even though the survival benefit of sorafenib is
about 3 months for HCC patients with Child-Pugh Class
A liver function, and less infrequent side effects such as
hand-foot skin reaction (HFSR) [41,42].
Compared with these small molecules, PDOX could
be termed as a “passive targeting agent”, which exerts its
effect by Cat B cleavage. Normal organs are protected by
masking the cytotoxic drug DOX with a simple dipep-
tide that renders it nontoxic. At the tumor the mask is
removed by Cat B, a ubiquitous proteolytic enzyme that
is so destructive to tissue that normally it occurs only
within cells, encased in lysosomes. Only tumor cells se-
crete Cat B externally, confined to their plasma mem-
branes, for the purpose of penetrating basement
membrane and extracellular barriers during cancer inva-
sion. The prodrug PDOX is rapidly cleaved by Cat B at
the Phe-Lys bond. The resulting PABC-DOX decom-
poses at once to para-aminobenzyl alcohol, CO2 and free
DOX. Furthermore, PDOX kills metastatic cancer cells
(which are normally harder to kill than primary tumor
cells) more powerfully than free DOX itself.
In summary, this study has provided more supporting
evidence to show that PDOX does have increased anti-
metastatic effects and reduced side effects especially
the cardio-toxicity in this highly metastatic HCC model
system. PDOX could be a promising new drug candi-
date for molecular targeting therapy of HCC.
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